{"id":"W4379281157","doi":"10.1200/jco.2023.41.16_suppl.8003","title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary; Princess Margaret Cancer Centre","funders":"Janssen Research and Development","keywords":"Medicine; Daratumumab; Internal medicine; Refractory (planetary science); CD38; Oncology; Tolerability; Gastroenterology; Proteasome inhibitor; Lenalidomide; Multiple myeloma; Adverse effect; CD34","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002052891,0.0005202194,0.001050648,0.0005862779,0.0001661937,0.0008703392,0.000436439,0.0004669052,0.001626029],"category_scores_gemma":[0.001311165,0.0002130817,0.00163136,0.0009180567,0.0001366444,0.000515413,0.0003566223,0.0006230661,0.0004677889],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000676377,"about_ca_system_score_gemma":0.0005925433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001912147,"about_ca_topic_score_gemma":0.005428071,"domain_scores_codex":[0.9994646,0.0001822391,0.00008967346,0.00007993755,0.0001240267,0.00005951909],"domain_scores_gemma":[0.9989954,0.0002731248,0.0004005664,0.0000413917,0.0001354739,0.0001539641],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.08322936,0.001807521,0.2583361,0.00502997,0.01026745,0.0006403109,0.0003428663,0.003060054,0.008747048,0.0001792606,0.01906109,0.609299],"study_design_scores_gemma":[0.02303457,0.05283329,0.8305169,0.001811751,0.02522487,0.003963497,0.0003174982,0.003105385,0.004998214,0.0003755144,0.05370047,0.0001181052],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8420865,0.1353531,0.001105545,0.001994444,0.000283133,0.0007806701,0.009833295,0.0001799738,0.008383519],"genre_scores_gemma":[0.9479215,0.03141899,0.002039267,0.002161209,0.0004020592,0.0003631211,0.01412836,0.00003734155,0.00152823],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002052891,"threshold_uncertainty_score":0.01085687,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1027499321914212,"score_gpt":0.4408975407525841,"score_spread":0.3381476085611629,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}